Catalent Announces New Board Appointments
Catalent has appointed three new directors to its Board: Susan Mahony, Marie-France Tschudin, and Tim Walbert, as the company continues its growth under Novo Holdings' ownership. The appointments are effective immediately and complete the company's Board updates, bringing the total to 7 directors.
The Board also includes Jonathan Levy (Senior Partner) and Charles Patten (Partner) from Novo Holdings, who joined following Catalent's transition to a private company after its acquisition by Novo Holdings in December 2024. Alessandro Maselli, President and CEO, expressed enthusiasm about working with the new Board members to drive continued growth as an independent CDMO.
Board Chair John Greisch highlighted that these biopharma leaders' expertise in navigating healthcare complexities will be valuable for Catalent's mission to develop, manufacture, and supply products that improve people's lives.
Catalent ha nominato tre nuovi direttori per il suo Consiglio: Susan Mahony, Marie-France Tschudin e Tim Walbert, mentre l'azienda continua la sua crescita sotto la proprietà di Novo Holdings'. Le nomine sono effettive immediatamente e completano gli aggiornamenti del Consiglio, portando il totale a 7 direttori.
Il Consiglio include anche Jonathan Levy (Senior Partner) e Charles Patten (Partner) di Novo Holdings, che si sono uniti dopo la transizione di Catalent a una società privata in seguito all'acquisizione da parte di Novo Holdings nel dicembre 2024. Alessandro Maselli, Presidente e CEO, ha espresso entusiasmo nel collaborare con i nuovi membri del Consiglio per guidare una continua crescita come CDMO indipendente.
Il Presidente del Consiglio, John Greisch, ha sottolineato che l'esperienza di questi leader biopharma nella gestione delle complessità sanitarie sarà preziosa per la missione di Catalent di sviluppare, produrre e fornire prodotti che migliorano la vita delle persone.
Catalent ha nombrado a tres nuevos directores para su Junta: Susan Mahony, Marie-France Tschudin y Tim Walbert, mientras la empresa continúa su crecimiento bajo la propiedad de Novo Holdings'. Las nombramientos son efectivos de inmediato y completan las actualizaciones de la Junta, llevando el total a 7 directores.
La Junta también incluye a Jonathan Levy (Socio Senior) y Charles Patten (Socio) de Novo Holdings, quienes se unieron tras la transición de Catalent a una empresa privada después de su adquisición por Novo Holdings en diciembre de 2024. Alessandro Maselli, Presidente y CEO, expresó su entusiasmo por trabajar con los nuevos miembros de la Junta para impulsar un crecimiento continuo como CDMO independiente.
El Presidente de la Junta, John Greisch, destacó que la experiencia de estos líderes biopharma en la navegación de las complejidades del sistema de salud será valiosa para la misión de Catalent de desarrollar, fabricar y suministrar productos que mejoran la vida de las personas.
카탈렌트는 이사회에 새로운 이사로 수잔 마호니, 마리-프랑스 추디, 팀 월버트를 임명했습니다. 이는 회사가 노보 홀딩스 소속 아래 성장하는 가운데 이루어졌습니다. 이 임명은 즉시 효력이 발생하며 이사회 업데이트를 완료하여 총 7명의 이사가 되었습니다.
이사회에는 노보 홀딩스의 조너선 레비(선임 파트너)와 찰스 패튼(파트너)도 포함되어 있으며, 이들은 2024년 12월 노보 홀딩스에 인수된 후 카탈렌트가 비상장 회사로 전환하면서 합류하게 되었습니다. 알레산드로 마셀리, 사장 겸 CEO는 독립적인 CDMO로서 지속적인 성장을 추진하기 위해 새로운 이사들과 협력하게 되어 매우 기쁘다고 밝혔습니다.
이사회 의장 존 그라이쉬는 이러한 생명공학 리더들이 의료 복잡성을 탐색하는 데 있어 갖춘 전문성이 카탈렌트의 사명인 사람들의 삶을 개선하는 제품을 개발, 제조 및 공급하는 데 있어 귀중할 것이라고 강조했습니다.
Catalent a nommé trois nouveaux directeurs à son Conseil : Susan Mahony, Marie-France Tschudin et Tim Walbert, alors que l'entreprise continue sa croissance sous la propriété de Novo Holdings'. Les nominations prennent effet immédiatement et complètent les mises à jour du Conseil, portant le total à 7 directeurs.
Le Conseil comprend également Jonathan Levy (Partenaire Senior) et Charles Patten (Partenaire) de Novo Holdings, qui ont rejoint après la transition de Catalent vers une entreprise privée suite à son acquisition par Novo Holdings en décembre 2024. Alessandro Maselli, Président et CEO, a exprimé son enthousiasme à travailler avec les nouveaux membres du Conseil pour favoriser une croissance continue en tant que CDMO indépendant.
Le Président du Conseil, John Greisch, a souligné que l'expertise de ces leaders biopharmaceutiques dans la navigation des complexités du secteur de la santé sera précieuse pour la mission de Catalent de développer, fabriquer et fournir des produits qui améliorent la vie des gens.
Catalent hat drei neue Direktoren in seinen Vorstand berufen: Susan Mahony, Marie-France Tschudin und Tim Walbert, während das Unternehmen unter der Eigentümerschaft von Novo Holdings' weiter wächst. Die Ernennungen treten sofort in Kraft und vervollständigen die Aktualisierungen des Vorstands, sodass es insgesamt 7 Direktoren gibt.
Dem Vorstand gehören auch Jonathan Levy (Senior Partner) und Charles Patten (Partner) von Novo Holdings an, die nach Catalents Übergang zu einem privaten Unternehmen nach der Übernahme durch Novo Holdings im Dezember 2024 beigetreten sind. Alessandro Maselli, Präsident und CEO, äußerte seine Begeisterung über die Zusammenarbeit mit den neuen Vorstandsmitgliedern, um das kontinuierliche Wachstum als unabhängiger CDMO voranzutreiben.
Der Vorsitzende des Vorstands, John Greisch, hob hervor, dass die Expertise dieser Biopharma-Führungskräfte im Umgang mit den Komplexitäten des Gesundheitswesens für die Mission von Catalent, Produkte zu entwickeln, herzustellen und bereitzustellen, die das Leben der Menschen verbessern, von großem Wert sein wird.
- Strengthened board composition with three experienced biopharma industry leaders
- Completed transition to private ownership under Novo Holdings
- Board expansion supports strategic growth as independent CDMO
- None.
Adds three new directors with deep expertise across biopharma and life sciences
Alessandro Maselli, President and CEO, and Board member of Catalent, said “I am excited to work closely with these new Board members as we drive continued growth as an independent CDMO delivering unparalleled service to our pharma and biotech customers. Susan, Marie-
“We are thrilled to welcome these biopharma leaders to our Board, whose expertise in navigating the complexities of the healthcare landscape will be invaluable," said John Greisch, Chair of the Board. "We look forward to benefitting from their insights in support of Catalent’s mission to develop, manufacture and supply products that help people live better and healthier lives.”
The Catalent Board also includes Jonathan Levy, Senior Partner at Novo Holdings, and Charles Patten, Partner at Novo Holdings, both of whom joined the Board upon Catalent becoming a private company following the completion of the acquisition by Novo Holdings in December 2024.
“On behalf of Novo Holdings, I am pleased to welcome our new Board members, said Jonathan Levy, Senior Partner, Novo Holdings. “Their diverse expertise and strategic insight will strengthen Catalent’s operations as an independent CDMO. We look forward to their contributions as we shape the company’s next chapter of growth and continued focus on improving the lives of patients worldwide.”
The appointment of these new Board Directors is effective immediately and completes the Company’s updates to its Board, which is now comprised of 7 directors.
About Sue Mahony
Sue Mahony is a senior executive with over 30 years of experience in pharmaceutical and life sciences companies. Dr. Mahony served in a variety of senior leadership positions at Eli Lilly and Company from 2000 to 2018, most recently as Senior Vice President and President of Lilly Oncology and a member of the executive committee of Eli Lilly. Prior to joining Lilly, Dr. Mahony served in sales and marketing roles in
About Marie-France Tschudin
Marie-France Tschudin is a global healthcare leader with 30 years of experience in the biotechnology and pharma industry. Until September 2023, Ms. Tschudin was President, Innovative Medicines International & Chief Commercial Officer of Novartis Pharma AG and a member of the Executive Committee. Before that, she held increasingly senior leadership positions, including President, Novartis Pharmaceuticals. Prior to joining Novartis, Ms. Tschudin spent 10 years at Celgene International in a variety of leadership positions across
About Tim Walbert
Tim Walbert served as the Chairman, President and Chief Executive Officer of Horizon Therapeutics from 2008 to October 2023, when it was acquired by Amgen for
About Catalent
Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) whose mission is to develop, manufacture, and supply products that help people live better and healthier lives. Catalent is dedicated to delivering unparalleled service to pharma, biotech, and consumer health customers, supporting product development, launch, and full life-cycle supply. With time-tested experience in development sciences, delivery technologies, and multi-modality manufacturing, Catalent supports the acceleration of development programs and the launch of more than a hundred new products every year. Powered by thousands of scientists and technicians and the latest technology platforms at more than 40 global sites, Catalent supplies billions of doses of life-enhancing and life-saving treatments for patients annually. For more information, visit www.catalent.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250219474614/en/
Media Contact:
Laura Hortas
+1 (609) 240-7025
media@catalent.com
Source: Catalent, Inc.
FAQ
Who are the new board members appointed to Catalent (CTLT) in 2024?
How many directors are now on Catalent's board after the new appointments?
When did Novo Holdings complete its acquisition of Catalent?
Which Novo Holdings executives joined Catalent's board after the acquisition?
